Alumis Inc. (ALMS) stock
ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.60−0.53 (-8.65%)
Close on Nov 13, 2026Market cap $724.84MP/E –Yield –
Alumis ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Alumis's ebitda for the twelve months ending Sep 30, 2026 was -$439.35M. For fiscal 2025 it was -$450.31M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$450.31M | – |
| FY2024 | Dec 31, 2024 | -$297.60M | – |
| FY2023 | Dec 31, 2023 | -$156.89M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$98.18M | – |
| Q2 FY2026 | Jun 30, 2026 | -$148.06M | – |
| Q1 FY2026 | Mar 31, 2026 | -$97.54M | – |
| Q4 FY2025 | Dec 31, 2025 | -$95.58M | – |
| Q3 FY2025 | Sep 30, 2025 | -$114.39M | – |
| Q2 FY2025 | Jun 30, 2025 | -$139.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$100.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$97.80M | – |
| Q3 FY2024 | Sep 30, 2024 | -$97.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$55.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$46.84M | – |
| Q4 FY2023 | Dec 31, 2023 | -$39.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -$43.46M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.52M | – |
See a number that looks wrong?